# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2020

# OMEROS CORPORATION

(Exact name of Registrant as Specified in Its Charter)

Washington (State or Other Jurisdiction of Incorporation) 001-34475 (Commission File Number) 91-1663741 (IRS Employer Identification No.)

201 Elliott Avenue West Seattle, WA (Address of Principal Executive Offices)

98119 (Zip Code)

Registrant's Telephone Number, Including Area Code: (206) 676-5000

(Former Name or Former Address, if Changed Since Last Report)

	Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):			
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)			
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)			
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))			
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			
Securities Registered Pursuant to Section 12(b) of the Act:				
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered	

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.01 par value per share	OMER	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 under the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company  $\square$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

### Item 5.07 Submission of Matters to a Vote of Security Holders.

Omeros Corporation ("Omeros" or the "Company") held its 2020 Annual Meeting of Shareholders on June 5, 2020 (the "Annual Meeting"). Shareholders of record at the close of business on April 13, 2020 were entitled to vote 54,510,667 shares of common stock at the Annual Meeting. A total of 45,002,862 shares (82.6%) were represented at the Annual Meeting in person or by proxy. Set forth below is a brief description of each matter voted upon at the Annual Meeting and the final voting results for each matter.

(1) The following individuals were elected to serve as directors by the vote set forth below. Mr. Thomas J. Cable, Dr. Peter Demopulos, and Mr. Kurt Zumwalt were elected as Class II directors, each to serve until the 2023 Annual Meeting of Shareholders of Shareholders, or, in each case, until his successor is duly elected and qualified, or until his earlier death, resignation or removal.

				Broker Non-
	For	Against	Abstain	Votes
Thomas J. Cable	20,663,275	6,762,866	461,617	17,115,104
Peter A. Demopulos, M.D.	25,790,712	1,745,633	351,413	17,115,104
Kurt Zumwalt	27,204,561	439,544	243,653	17,115,104

(2) Shareholders approved an advisory resolution regarding the compensation of Omeros' named executive officers as reported in the proxy statement for the 2020 Annual Meeting of Shareholders by the vote set forth below.

			Broker Non-
For	Against	Abstain	Votes
25,967,469	1,316,736	603,553	17,115,104

(3) Shareholders ratified the appointment of Ernst & Young LLP as Omeros' independent registered public accounting firm for the fiscal year ending December 31, 2019 by the vote set forth below.

			Broker Non-
For	Against	Abstain	Votes
43,923,851	661,300	417,711	17,115,104

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 11, 2020

## **OMEROS CORPORATION**

By: /s/ Gregory A. Demopulos

Gregory A. Demopulos, M.D.
President, Chief Executive Officer and
Chairman of the Board of Directors